Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Pharmaceutical giant Eli Lilly (LLY) has promised to make its new weight-loss pill in the U.S. as President Donald Trump ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Most U.S. stocks rose, but the worst drop for UnitedHealth Group in a quarter century kept Wall Street in check.

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

Eli Lilly shares are now positive for the year, up 10% since the start of January.

U.S. stocks are holding steadier in the final day of trading for their holiday-shortened week. The S&P 500 rose 0.2% Thursday ...